Ok_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":875440756,"tweetId":"875440756","gmtCreate":1637681005785,"gmtModify":1637681005877,"author":{"id":3585281594587734,"idStr":"3585281594587734","authorId":3585281594587734,"authorIdStr":"3585281594587734","name":"jazzman","avatar":"https://static.tigerbbs.com/576ea0bb835315d386051f7c315a382e","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":15,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/875440756","repostId":1156228294,"repostType":4,"repost":{"id":"1156228294","pubTimestamp":1637679908,"share":"https://www.laohu8.com/m/news/1156228294?lang=&edition=full","pubTime":"2021-11-23 23:05","market":"us","language":"en","title":"Aptevo Stock Rallies After Posting First Complete Remission In Early Acute Myeloid Leukemia Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1156228294","media":"Benzinga","summary":"Aptevo Therapeutics Inc has announced a clinical update for its Phase 1b Expansion trial evaluating ","content":"<ul>\n <li><b>Aptevo Therapeutics Inc</b>&nbsp;has announced a clinical update for its Phase 1b Expansion trial evaluating APVO436 for acute myeloid leukemia (AML).</li>\n</ul>\n<ul>\n <li>A high-risk AML patient treated in Cohort 1 with a combination of chemotherapy plus APVO436&nbsp;achieved a complete remission&nbsp;(CR) after one cycle of therapy.</li>\n <li>The chemotherapy regimen included the standard leukemia drugs Mitoxantrone, Etoposide, and Cytarabine.</li>\n <li>The patient tolerated treatment without evidence of over toxicity.</li>\n <li>Overexpression of CD123 is the hallmark of many forms of leukemia. Aptevo's lead proprietary drug candidate, APVO436, is a bispecific CD3xCD123 ADAPTIR designed to redirect the patient's immune system to destroy leukemia cells expressing the target CD123 molecule on their surface.</li>\n <li><b>Price Action:</b>&nbsp;APVO shares are up 54.6% at $10.02 during the morning session on the last check Tuesday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptevo Stock Rallies After Posting First Complete Remission In Early Acute Myeloid Leukemia Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptevo Stock Rallies After Posting First Complete Remission In Early Acute Myeloid Leukemia Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24248635/aptevo-stock-rallies-after-posting-first-complete-remission-in-early-acute-myeloid-leukemia-trial><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aptevo Therapeutics Inc has announced a clinical update for its Phase 1b Expansion trial evaluating APVO436 for acute myeloid leukemia (AML).\n\n\nA high-risk AML patient treated in Cohort 1 with a ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24248635/aptevo-stock-rallies-after-posting-first-complete-remission-in-early-acute-myeloid-leukemia-trial\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"APVO":"Aptevo Therapeutics Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/11/24248635/aptevo-stock-rallies-after-posting-first-complete-remission-in-early-acute-myeloid-leukemia-trial","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156228294","content_text":"Aptevo Therapeutics Inc has announced a clinical update for its Phase 1b Expansion trial evaluating APVO436 for acute myeloid leukemia (AML).\n\n\nA high-risk AML patient treated in Cohort 1 with a combination of chemotherapy plus APVO436 achieved a complete remission (CR) after one cycle of therapy.\nThe chemotherapy regimen included the standard leukemia drugs Mitoxantrone, Etoposide, and Cytarabine.\nThe patient tolerated treatment without evidence of over toxicity.\nOverexpression of CD123 is the hallmark of many forms of leukemia. Aptevo's lead proprietary drug candidate, APVO436, is a bispecific CD3xCD123 ADAPTIR designed to redirect the patient's immune system to destroy leukemia cells expressing the target CD123 molecule on their surface.\nPrice Action: APVO shares are up 54.6% at $10.02 during the morning session on the last check Tuesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":835,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/875440756"}